Clinical evaluation reports effective disease management in systemic sclerosis patients, highlighting frequent low-dose rituximab as a viable long-term treatment strategy.
Systemic sclerosis (SSc) is a multiorgan disease with a 10-year mortality rate of up to 50 %. B cell-depleting therapy with rituximab (RTX) appears effective in SSc treatment, but data from randomized controlled trials (RCTs) are lacking, and the frequency and dosage of RTX in SSc have no consensus. We aimed to evaluate the long-term efficacy and safety of quarterly RTX administration in SSc.
No takes yet. Share an insight, caveat, or question.
Moazedi‐Fuerst et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: